LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Amphastar Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERAMPH
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / AMPH COVERAGE

What’s moving Amphastar Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection

Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection

The story matters when it changes Amphastar Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript

Investors are testing whether Amphastar Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Amphastar Pharmaceuticals, Inc. Being Investigated on Behalf of Amphastar Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details

Amphastar Pharmaceuticals, Inc. Being Investigated on Behalf of Amphastar Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details

The development tests whether Amphastar Pharmaceuticals, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
04
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript

Investors are testing whether Amphastar Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2024 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2024 Earnings Call Transcript

Investors are testing whether Amphastar Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest AMPH filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-13 · Period 2026-07-09SEC ↗8-KMaterial company eventFiled 2026-07-08 · Period 2026-07-02SEC ↗8-KMaterial company eventFiled 2026-06-03 · Period 2026-06-01SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-13 · Period 2026-06-01SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-14SEC ↗
EARNINGS / QUARTERLY TRACKER

Amphastar Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.